Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage TechBio company that regularly issues news and updates about its platform, pipeline and partnerships. As a biotechnology company focused on decoding biology to radically improve lives, Recursion generates announcements that span clinical trial readouts, business development milestones and technology advances related to its Recursion OS.
News for RXRX often highlights progress in clinical programs, such as the TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP), the ELUCIDATE Phase 1/2 trial of REC-617 in advanced solid tumors and ovarian cancer, and the DAHLIA Phase 1/2 study of REC-1245 in solid tumors. Company communications describe efficacy, safety, and design details for these studies, as well as plans for future data readouts and regulatory interactions.
Investors also see frequent updates on partnerships and collaborations. Recursion reports milestones from its long-term collaboration with Genentech and F. Hoffmann-La Roche Ltd, including acceptance of whole-genome phenotypic maps such as a microglia map, and from its multi-target collaboration with Sanofi in oncology and immunology. These items often include information about milestone payments and the scope of ongoing discovery work.
Additional RXRX news covers financial results and capital markets activity, such as quarterly earnings releases, cash runway commentary, and disclosures related to registration statements and share issuances connected to collaborations or acquisitions. The company also announces participation in healthcare and investor conferences, webinars on clinical data, and leadership changes, including CEO transition plans.
By following the RXRX news feed, readers can track how Recursion’s Recursion OS platform is being applied across its internal pipeline and partnered programs, as well as how business decisions, collaborations and governance developments may shape the company’s trajectory in the TechBio and biotechnology sectors.
Recursion (NASDAQ: RXRX) announced its expansion into Toronto, aiming to hire up to 50 professionals by the end of 2021 across various disciplines, including data science and computational biology. This marks their first major hub outside Utah, aligning with the company’s strategy to leverage Toronto's diverse talent pool. Currently, Recursion employs over 260 staff and has grown by over 60% in the past year. The Toronto hub will support the development of its extensive therapeutic pipeline and the Recursion Operating System, which facilitates advanced drug discovery.
Recursion Pharmaceuticals (Nasdaq: RXRX) announced the initiation of IND-enabling studies for REC-163964, a small molecule toxin inhibitor aimed at preventing recurrent C. difficile infections. This candidate is the first internally-discovered New Chemical Entity identified by the company’s ML-enabled Operating System. C. difficile infections cause significant morbidity in over 730,000 patients annually in the US and EU, with high recurrence rates. CEO Chris Gibson highlighted the importance of their growing data library for future drug developments.
Recursion Pharmaceuticals (RXRX) reported Q1 2021 financial results, showcasing significant progress in its clinical and research programs. The company ended the quarter with $214.1 million in cash, following a successful IPO in April, raising $462.6 million. Revenue surged to $2.6 million, driven by collaboration with Bayer, while R&D expenses increased to $24.1 million due to heightened activities. Net loss widened to $30.7 million. The company is advancing multiple clinical programs and expanding its inferential search platform, contributing to a robust pipeline of 37 development programs.
Recursion Pharmaceuticals closed its initial public offering on April 20, 2021, raising $501.8 million through the sale of 27,878,787 shares of Class A common stock at $18.00 per share. This includes the full exercise of the underwriters' option for an additional 3,636,363 shares. Trading commenced on the Nasdaq Global Select Market under the ticker RXRX on April 16, 2021. Goldman Sachs and J.P. Morgan were the lead book-running managers for the offering.
Recursion Pharmaceuticals has priced its initial public offering (IPO) of 24,242,424 shares of Class A common stock at $18.00 per share, aiming to raise $436.4 million in gross proceeds. The shares will start trading on the Nasdaq under the symbol RXRX on April 16, 2021, with the offering expected to close by April 20, 2021. The underwriters have a 30-day option to purchase an additional 3,636,363 shares. Goldman Sachs & Co. LLC and J.P. Morgan are leading the underwriting for this offering.